Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
